EpiPen 'Failures': More Bad Headlines For Mylan – And Reminder Of FDA's Own Risks
Executive Summary
Latest headlines about EpiPen cite deaths associated with product 'failures.' The attention is probably unfair, given the source (US FDA adverse event reports) but it is also inevitable given the history – and may be a warning of headlines to come if and when a generic is approved.